A Phase 2 interventional study of Megestrol acetate oral suspension nanocrystal dispersion 115 mg/mL and Megestrol acetate oral suspension 40 mg/mL in HIV Infections, Cachexia and Anorexia, sponsored by Endo Pharmaceuticals. Completed at 12 sites in 3 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2017-10-05.
Sponsored by Endo Pharmaceuticals (part of Keenova Therapeutics plc) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 305 studies in HIV Infections with a site in South Africa — 15 open to participants now, 36 under way, 15 of them phase 3. HIV Infections · South Africa.
Among the 305 studies in HIV Infections with a site in South Africa, this one is the 211th largest by enrollment of the 267 interventional ones that give a count, is one of 11 that started in 2004, is one of 54 in phase 2, and was the 98th registered.
4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.
Browse HIV Infections studies →15 of the 305 studies in HIV Infections with a site in South Africa are open now. Recruiting first, the newest first:
ViiV Healthcare · Sites in South Africa, Romania, Uganda
ViiV Healthcare · Sites in South Africa
Ages up to 10 days · Healthy volunteers
Emory University · Sites in South Africa
Ages 18+ · Men only · Healthy volunteers
University of Illinois at Chicago · Sites in South Africa
Ages 18+ · Healthy volunteers
University of California, San Francisco · Sites in South Africa
A study can be open while its sites in South Africa have not opened yet or have stopped. Only those recruiting at a site in South Africa →
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
305 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 60 · Phase 2 92 · Phase 3 85 · Phase 4 21
First in 1999; this study’s year is marked. 11 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 63 is below the median of 80 across 3,492 interventional studies indexed under HIV Infections.
Median enrollment 280 across the 267 interventional studies, 513 across the 35 observational. Of the 248 that completed or were terminated, 128 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
77 of 305 have an industry lead sponsor. The 10 most frequent:
This study is registered under Endo Pharmaceuticals, one of the names counted as Keenova Therapeutics plc. Under that name alone:
Endo Pharmaceuticals is the lead sponsor of 99 studies on the registry; none are open to participants now.
Of its 16 completed or terminated interventional studies of FDA-regulated products, 14 (88%) have results posted.
Keenova Therapeutics plc has 2 studies filed under HIV Infections — fewer than ten, so there is no comparison to draw.
9 of the studies in HIV Infections with a site in South Africa that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06694753International AIDS Vaccine InitiativeSafety and Immunogenicity Study of Three mRNAs Encoding HIV Immunogens in Adult Participants Without HIV and in Overall Good Health in South Africa. | 2026-12-08 |
| NCT05602376Desmond Tutu HIV FoundationImproving HIV Testing, Linkage, and Retention in Care for Men Through U=U Messaging | 2026-12-31 |
| NCT05553236University of California, San FranciscoPragmatic Use of Next-generation Sequencing for Management of Drug-resistant Tuberculosis | 2027-01 |
| NCT05933226University of Maryland, College ParkProject Khanya: Peer-Delivered Intervention to Improve HIV Medication Adherence and Substance Use in South Africa | 2027-02 |
| NCT05633056Columbia UniversityAn Adaptive Randomized Controlled Trial | 2027-04 |
Add all 9 to your calendar (.ics) → With an account.
Among the 305 studies in HIV Infections with a site in South Africa, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Explore weight gain in HIV-positive patients who have weight loss associated with AIDS-related wasting (anorexia/cachexia). Patients are treated for 12 weeks with either megestrol acetate oral suspension nanocrystal dispersion formulation, or megestrol acetate oral suspension original formulation
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Megestrol acetate oral suspension nanocrystal dispersion formulation 115 mg/mL
Drug: Megestrol acetate oral suspension nanocrystal dispersion 115 mg/mL
Megestrol acetate oral suspension micronized formulation 60 mg/mL
Drug: Megestrol acetate oral suspension 40 mg/mL
Drug page: Megestrol Acetate
Megestrol acetate oral suspension nanocrystal dispersion 115 mg/mL administered as 575 mg once per day (5 mL dose)
Also known as: Megace ES
Drug page: Megestrol Acetate
Megestrol acetate oral suspension 40 mg/mL administered as 800 mg once per day (20 mL dose)
Also known as: Megace
Change in Body Weight
Weight gain in adult HIV positive subjects who have weight loss with AIDS related wasting within the first 12 weeks of treatment
Time frame: Baseline (Day 1) to Week 12
Change From Baseline in Lean Mass
Time frame: Baseline (Day 1) to Week 12
Change From Baseline in Impedance
Electrical impedance is a method for body composition assessment. The procedure involves sending a small current through the body and measuring the resistance in ohm. High resistance is associated with smaller amounts of fat-free mass. Smaller resistance is associated with large amounts of fat-free mass.
Time frame: Baseline (Day 1) to Week 12
Change From Baseline in Body Fat Mass
Time frame: Baseline (Day 1) to Week 12
Change in Hip Circumference
Time frame: Baseline (Day 1) to Week 12
Change in Waist Circumference
Time frame: Baseline (Day 1) to Week 12
Change in Tricep Skinfold
Time frame: Baseline (Day 1) to Week 12
Change in Mid-arm Circumference
Time frame: Baseline (Day 1) to Week 12
Change in Total Energy
Food intake was quantified by the 24-hour recall food diary
Time frame: Baseline (Day 1) to Week 12
Quality of Life (QoL) Via Bristol-Myers Anorexia/Cachexia Recovery Instrument (BACRI) at Baseline (Day 3) and Week 12 (BACRI)
The BACRI instrument is used to measure the benefit of weight gain treatment provided to anorexic patients on health related quality of life aspects. The scale is composed of 9 subscales (0 to 10 \[worse to better\]). The response was captured on a VAS scale in cm. The total BACRI score is the sum with a minimum score 0=worse and maximum score 90=better. These subscales are: change in weight impacting health; concern about weight; appearance change; change feeling of appearance; change in appetite; enjoy eating; overall feeling; benefit of treatment; and quality of life.
Time frame: Baseline (Day 3) to Week 12
Appetite at Baseline (Day 3) and Week 12
Appetite was assessed via visual analogue scale (VAS) as part of the Bristol-Myers Anorexia/Cachexia Recovery Instrument (BACRI) (Question 5 only). The question was "To what extent has your appetite changed since the start of treatment?" The response was captured on a VAS scale in cm with a range from 0 ( "much worse") to 10 ("much better").
Time frame: Baseline (Day 3) to Week 12
| Milestone | Megestrol Acetate Oral Suspension Nanocrystal Dispersion | Megestrol Acetate Oral Suspension Micronized Formulation |
|---|---|---|
| Started | 32 | 31 |
| Completed | 29 | 24 |
| Not completed | 3 | 7 |
| Withdrew: Adverse event | 1 | 2 |
| Withdrew: Death | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Physician decision | 1 | 1 |
| Withdrew: Withdrawal by subject | 0 | 2 |
| Withdrew: Illicit drug use | 1 | 0 |
Weight gain in adult HIV positive subjects who have weight loss with AIDS related wasting within the first 12 weeks of treatment
| kg | Megestrol Acetate Oral Suspension Nanocrystal Dispersion | Megestrol Acetate Oral Suspension Micronized Formulation |
|---|---|---|
| Overall | 5.4 ± 5.32 | 3.5 ± 4.03 |
| Male | 7.0 ± 3.16 | 3.5 ± 4.72 |
| Female | 2.3 ± 7.18 | 3.5 ± 3.42 |
| kg | Megestrol Acetate Oral Suspension Nanocrystal Dispersion | Megestrol Acetate Oral Suspension Micronized Formulation |
|---|---|---|
| Change From Baseline in Lean Mass | 2.1 ± 3.74 | 1.3 ± 2.82 |
Electrical impedance is a method for body composition assessment. The procedure involves sending a small current through the body and measuring the resistance in ohm. High resistance is associated with smaller amounts of fat-free mass. Smaller resistance is associated with large amounts of fat-free mass.
| ohms | Megestrol Acetate Oral Suspension Nanocrystal Dispersion | Megestrol Acetate Oral Suspension Micronized Formulation |
|---|---|---|
| Change From Baseline in Impedance | 21.6 ± 77.2 | 12.2 ± 54.2 |
| kg | Megestrol Acetate Oral Suspension Nanocrystal Dispersion | Megestrol Acetate Oral Suspension Micronized Formulation |
|---|---|---|
| Change From Baseline in Body Fat Mass | 3.2 ± 4.1 | 2.2 ± 3.4 |
| cm | Megestrol Acetate Oral Suspension Nanocrystal Dispersion | Megestrol Acetate Oral Suspension Micronized Formulation |
|---|---|---|
| Change in Hip Circumference | 2.5 ± 3.7 | 1.8 ± 3.6 |
| cm | Megestrol Acetate Oral Suspension Nanocrystal Dispersion | Megestrol Acetate Oral Suspension Micronized Formulation |
|---|---|---|
| Change in Waist Circumference | 7.1 ± 4.9 | 5.4 ± 4.7 |
| cm | Megestrol Acetate Oral Suspension Nanocrystal Dispersion | Megestrol Acetate Oral Suspension Micronized Formulation |
|---|---|---|
| Change in Tricep Skinfold | 1.0 ± 2.6 | 1.5 ± 5.4 |
| cm | Megestrol Acetate Oral Suspension Nanocrystal Dispersion | Megestrol Acetate Oral Suspension Micronized Formulation |
|---|---|---|
| Change in Mid-arm Circumference | -0.6 ± 11.5 | 1.1 ± 1.5 |
Food intake was quantified by the 24-hour recall food diary
| kcal | Megestrol Acetate Oral Suspension Nanocrystal Dispersion | Megestrol Acetate Oral Suspension Micronized Formulation |
|---|---|---|
| Change in Total Energy | 215.9 ± 830.3 | 150.6 ± 1044.1 |
The BACRI instrument is used to measure the benefit of weight gain treatment provided to anorexic patients on health related quality of life aspects. The scale is composed of 9 subscales (0 to 10 \[worse to better\]). The response was captured on a VAS scale in cm. The total BACRI score is the sum with a minimum score 0=worse and maximum score 90=better. These subscales are: change in weight impacting health; concern about weight; appearance change; change feeling of appearance; change in appetite; enjoy eating; overall feeling; benefit of treatment; and quality of life.
| cm | Megestrol Acetate Oral Suspension Nanocrystal Dispersion | Megestrol Acetate Oral Suspension Micronized Formulation |
|---|---|---|
| Baseline (Day 3) | 52.3 ± 9.38 | 50.1 ± 7.31 |
| Week 12 | 67.6 ± 9.53 | 65.6 ± 14.78 |
Appetite was assessed via visual analogue scale (VAS) as part of the Bristol-Myers Anorexia/Cachexia Recovery Instrument (BACRI) (Question 5 only). The question was "To what extent has your appetite changed since the start of treatment?" The response was captured on a VAS scale in cm with a range from 0 ( "much worse") to 10 ("much better").
| cm | Megestrol Acetate Oral Suspension Nanocrystal Dispersion | Megestrol Acetate Oral Suspension Micronized Formulation |
|---|---|---|
| Baseline Day 3 | 6.1 ± 1.81 | 5.8 ± 1.16 |
| Week 12 | 8.4 ± 1.30 | 8.0 ± 2.14 |
Collected over Approximately 16 weeks (baseline [day 1] through week 12 plus 30-day follow-up). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Megestrol Acetate Oral Suspension NanoCrystal Dispersion | — | 14/32 (43.8%) | 30/32 (93.8%) |
| Megestrol Acetate Oral Suspension Micronized Formulation | — | 14/31 (45.2%) | 30/31 (96.8%) |
| Event | Megestrol Acetate Oral Suspension NanoCrystal Dispersion | Megestrol Acetate Oral Suspension Micronized Formulation |
|---|---|---|
| Blood cortisol abnormalInvestigations | 6/32 | 3/31 |
| Adrenal insufficiencyEndocrine disorders | 3/32 | 4/31 |
| AnaemiaBlood and lymphatic system disorders | 0/32 | 2/31 |
| Cardiac failure congestiveCardiac disorders | 1/32 | 2/31 |
| Adrenal suppressionEndocrine disorders | 2/32 | 2/31 |
| Pulmonary tuberculosisInfections and infestations | 0/32 | 2/31 |
| Blood cortisol decreasedInvestigations | 2/32 | 0/31 |
| AstheniaGeneral disorders | 0/32 | 1/31 |
| Death of unknown causeGeneral disorders | 0/32 | 1/31 |
| Oedema peripheralGeneral disorders | 0/32 | 1/31 |
| Event | Megestrol Acetate Oral Suspension NanoCrystal Dispersion | Megestrol Acetate Oral Suspension Micronized Formulation |
|---|---|---|
| Blood lactate dehydrogenase increasedInvestigations | 12/32 | 5/31 |
| Red cell distribution width increasedInvestigations | 9/32 | 5/31 |
| CoughRespiratory, thoracic and mediastinal disorders | 9/32 | 6/31 |
| Adrenal insufficiencyEndocrine disorders | 4/32 | 8/31 |
| Mean cell volume increasedInvestigations | 8/32 | 5/31 |
| HeadacheNervous system disorders | 8/32 | 6/31 |
| DyspepsiaGastrointestinal disorders | 6/32 | 2/31 |
| Mean cell haemoglobin increasedInvestigations | 5/32 | 5/31 |
| HypertensionVascular disorders | 5/32 | 5/31 |
| AstheniaGeneral disorders | 5/32 | 0/31 |
Analysis based on Intend to Treat (ITT) population; all randomized subjects who were dispensed medication and had at least one post-randomization visit.
| Age, Continuous(years) | Megestrol Acetate Oral Suspension Nanocrystal Dispersion | Megestrol Acetate Oral Suspension Micronized Formulation | Total |
|---|---|---|---|
| Mean | 37.3 ± 7.32 | 36.3 ± 7.22 | 36.8 ± 7.23 |
| Sex: Female, Male(Participants) | Megestrol Acetate Oral Suspension Nanocrystal Dispersion | Megestrol Acetate Oral Suspension Micronized Formulation | Total |
|---|---|---|---|
| Female | 11 | 16 | 27 |
| Male | 21 | 15 | 36 |
Plan to share: No
The record gives a start of Dec 2004, a primary completion of Jun 2005 and a completion of Jun 2005. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2016, 10 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Megestrol Acetate